Epirus Biopharmaceuticals Inc  

(Public, OTCMKTS:EPRSQ)   Watch this stock  
Find more results for NASDAQ:ZLCS
0.0000 (0.00%)
Sep 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.02 - 0.02
52 week 0.01 - 0.05
Open 0.02
Vol / Avg. 1,555.00/24,368.00
Mkt cap 484,410.00
P/E     -
Div/yield     -
EPS -2.53
Shares 26.18M
Beta 1.13
Inst. own 10%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -2025.65% -7444.79%
Operating margin -1993.40% -7315.83%
EBITD margin - -7375.61%
Return on average assets -97.67% -84.42%
Return on average equity -208.66% -151.78%
Employees 73 -
CDP Score - -


699 Boylston St Ste 8
BOSTON, MA 02116-2836
United States - Map
+1-617-6003497 (Phone)
+1-302-6555049 (Fax)

Website links


EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Officers and directors

Robert Ticktin Senior Vice President, General Counsel, Secretary
Age: 53
Vincent E. Aurentz Chief Business Officer